New paradigms in hypertrophic cardiomyopathy: Insights from genetics

Progress in Pediatric Cardiology

Volumn 31, Issue 2, 2011, Pages 93-98

  Ho, Carolyn Y ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiomyopathy; Echocardiography; Genetics; Hypertrophy

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DILTIAZEM; LOSARTAN; PLACEBO; SIMVASTATIN; SPIRONOLACTONE;

ARTICLE; BIOCHEMISTRY; DIASTOLIC DYSFUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HEART MUSCLE FIBROSIS; HETEROZYGOTE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SARCOMERE;

EID: 79955474493     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2011.02.005     Document Type: Article

References (49)

1. Niimura H., Bachinski L.L., Sangwatanaroj S., et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy [see comments]. N Engl J Med 1998, 338(18):1248-1257.
2. Maron B.J., Seidman J.G., Seidman C.E. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 44(11):2125-2132.
3. Seidman J.G., Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001, 104(4):557-567.
4. Richard P., Villard E., Charron P., Isnard R. The genetic bases of cardiomyopathies. J Am Coll Cardiol 2006, 48(9 Suppl.):A79-A89.
5. Ho C.Y., Seidman C.E. A contemporary approach to hypertrophic cardiomyopathy. Circulation 2006, 113(24):e858-e862.
6. Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003, 42(9):1687-1713.
7. Ho C.Y., Sweitzer N.K., McDonough B., et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002, 105(25):2992-2997.
8. Nagueh S.F., Bachinski L.L., Meyer D., et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 2001, 104(2):128-130.
9. Germans T., Wilde A.A., Dijkmans P.A., et al. Structural abnormalities of the nferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol 2006, 48(12):2518-2523.
10. Moon J.C., Mogensen J., Elliott P.M., et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 2005, 91(8):1036-1040.
11. Rubinshtein R, Glockner JF, Ommen SR, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail;3(1):51-8.
12. Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol;56(11):875-87.
13. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol;56(11):867-74.
14. Geisterfer-Lowrance A.A., Christe M., Conner D.A., et al. A mouse model of familial hypertrophic cardiomyopathy. Science 1996, 272(5262):731-734.
15. Georgakopoulos D., Christe M.E., Giewat M., Seidman C.M., Seidman J.G., Kass D.A. The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation [see comments]. Nat Med 1999, 5(3):327-330.
16. Blanchard E., Seidman C., Seidman J.G., LeWinter M., Maughan D. Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. Circ Res 1999, 84(4):475-483.
17. Spindler M., Saupe K.W., Christe M.E., et al. Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest 1998, 101(8):1775-1783.
18. Fatkin D., McConnell B.K., Mudd J.O., et al. An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest 2000, 106(11):1351-1359.
19. Semsarian C., Ahmad I., Giewat M., et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 2002, 109(8):1013-1020.
20. Tardiff J.C. Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev 2005, 10(3):237-248.
21. Debold E.P., Schmitt J.P., Patlak J.B., et al. Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay. Am J Physiol Heart Circ Physiol 2007, 293(1):H284-H291.
22. Nagueh S.F., Kopelen H.A., Lim D.S., et al. Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2000, 102(12):1346-1350.
23. Ho C.Y., Carlsen C., Thune J.J., et al. Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2009, 2:314-321.
24. D'Hooge J., Heimdal A., Jamal F., et al. Regional strain and strain rate measurements by cardiac ultrasound: principles, implementation and limitations. Eur J Echocardiogr 2000, 1(3):154-170.
25. Edvardsen T., Gerber B.L., Garot J., Bluemke D.A., Lima J.A., Smiseth O.A. Quantitative assessment of intrinsic regional myocardial deformation by Doppler strain rate echocardiography in humans: validation against three-dimensional tagged magnetic resonance imaging. Circulation 2002, 106(1):50-56.
26. Serri K., Reant P., Lafitte M., et al. Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006, 47(6):1175-1181.
27. Abraham T.P., Dimaano V.L., Liang H.Y. Role of tissue Doppler and strain echocardiography in current clinical practice. Circulation 2007, 116(22):2597-2609.
28. Mirsky I., Parmley W.W. Assessment of passive elastic stiffness for isolated heart muscle and the intact heart. Circ Res 1973, 33(2):233-243.
29. Sutherland G.R., Di Salvo G., Claus P., D'Hooge J., Bijnens B. Strain and strain rate imaging: a new clinical approach to quantifying regional myocardial function. J Am Soc Echocardiogr 2004, 17(7):788-802.
30. Bellavia D., Pellikka P.A., Abraham T.P., et al. Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol 2008, 101(7):1039-1045.
31. Koyama J., Ray-Sequin P.A., Falk R.H. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003, 107(19):2446-2452.
32. Crilley J.G., Boehm E.A., Blair E., et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003, 41(10):1776-1782.
33. Ashrafian H., Watkins H. Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications cardiomyopathies: therapeutics based on molecular phenotype. J Am Coll Cardiol 2007, 49(12):1251-1264.
34. Basso C., Thiene G., Corrado D., Buja G., Melacini P., Nava A. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 2000, 31(8):988-998.
35. Shirani J., Pick R., Roberts W.C., Maron B.J. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000, 35(1):36-44.
36. Choudhury L., Mahrholdt H., Wagner A., et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 40(12):2156-2164.
37. Varnava A.M., Elliott P.M., Mahon N., Davies M.J., McKenna W.J. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol 2001, 88(3):275-279.
38. Varnava A.M., Elliott P.M., Sharma S., McKenna W.J., Davies M.J. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 2000, 84(5):476-482.
39. Kim J.B., Porreca G.J., Song L., et al. Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science 2007, 316(5830):1481-1484.
40. Ho C.Y., Lopez B., Coelho-Filho O.R., et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010, 363(6):552-563.
41. Teekakirikul P., Eminaga S., Toka O., et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J Clin Invest 2010.
42. Lim D.S., Lutucuta S., Bachireddy P., et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001, 103(6):789-791.
43. Patel R., Nagueh S.F., Tsybouleva N., et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001, 104(3):317-324.
44. Tsybouleva N., Zhang L., Chen S., et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004, 109(10):1284-1291.
45. Marian A.J., Senthil V., Chen S.N., Lombardi R. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol 2006, 47(4):827-834.
46. Araujo A.Q., Arteaga E., Ianni B.M., Buck P.C., Rabello R., Mady C. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol 2005, 96(11):1563-1567.
47. Bauersachs J., Stork S., Kung M., et al. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. Eur J Clin Investig 2007, 37(11):852-859.
48. Kawano H., Toda G., Nakamizo R., Koide Y., Seto S., Yano K. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J 2005, 69(10):1244-1248.
49. Penicka M., Gregor P., Kerekes R., Marek D., Curila K., Krupicka J. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn 2009, 11(1):35-41.